Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: A phase I trial

Human Gene Therapy

Volumn 7, Issue 12, 1996, Pages 1465-1477

  Eck, Stephen L ^a   Alavi, Jane B ^a   Alavi, Abass ^a   Davis, Alan ^a   Hackney, David ^a   Judy, Kevin ^a   Mollman, Joan ^a   Phillips, Peter C ^a   Wheeldon, Eric B ^a   Wilson, James M ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE;

ADENOVIRUS; ADULT; ADVANCED CANCER; ANEMIA; BIRTH DEFECT; BONE MARROW SUPPRESSION; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DRUG SENSITIVITY; FEVER; GENE THERAPY; GLIOMA; GRANULOCYTOPENIA; HEADACHE; HERPES SIMPLEX VIRUS; HUMAN; HUMAN TISSUE; INFERTILITY; LIVER TOXICITY; METABOLISM; MINIMAL RESIDUAL DISEASE; NEPHROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; RASH; RECURRENT CANCER; REVIEW; THROMBOCYTOPENIA; TUMOR VOLUME; VIRUS RECOMBINANT;

EID: 19244362665     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.12-1465     Document Type: Review

References (60)

1. Boring, C.C., T.S. Squires, and T. Tong, Cancer Statistics. CA, Cancer J. Clinicians, 1993. 43: p. 7-26.
2. Burger, P.C., B.W. Scheithauer, and F.S. Vogel, Surgical pathology of the nervous system and its coverings. 3rd ed. 1991, New York, NY: Churchill Livingston.
3. Burger, P.C., E.R. Heinz, and T. Shibata, Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J. Neurosurgery, 1988. 68: p. 698-704.
4. Hochberg, F.H. and A. Pruitt. Assumptions in the radiotherapy of glioblastoma. Neurolog, 1980. 30: p. 907-911.
5. Mahaley, M.S.J., et al., National survey of patterns of care for brain-tumor patients. J. Neurosurg., 1989. 71: p. 826-836.
6. Curran, W.J.J., et al., Recurse partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J. Nat'l. Cancer Inst., 1993. 85: p. 704-710.
7. Leibel, S.A., C.B. Scott, and J.S. Loeffler, Contemporary approaches to the treatment of malignant gliomas with radiation therapy. Sem. Oncol., 1994. 21: p. 198-219.
8. Scharfen, C.O., et al. High activity I-125 interstitial implant for gliomas. Int. J. Radiat. Oncol. Biol. Phys., 1992. 24: p. 583-591.
9. Walker, M.D., et al., Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. New Eng. J. Med., 1980. 303: p. 1323-1329.
10. Kornblith, P.L. and M. Walker, Chemotherapy for malignant gliomas. J. Neurosurg., 1988. 68: p. 1-17.
11. Yung, W.K., et al., Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. J. Clin. Oncol., 1992, 9(11): p. 1945-9.
12. Merchant, R.E., et al., Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurgery, 1988. 23(6): p. 725-32.
13. Jaekle, K.A., Immunotherapy of malignant gliomas. Sem. Oncol., 1994. 21: p. 249-259.
14. Fine, H., et al., Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer, 1993. 71: p. 2585-97.
15. Ausman, J.I., et al., Brain-tumor chemotherapy. Pharmacological principles derived from a monkey brain-tumor model. J. Neurosurg., 1977. 46(2): p. 155-64.
16. Neuwelt, E.A., et al., Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery, 1986. 19(4): p. 573-582.
17. Brem, H., M.S.J. Mahaley, and N.A. Vick, Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J. Neurosurg., 1991. 74: p. 441-446.
18. Wolff, S.N., G.L. Phillips, and G.P. Herzig, High dose carmustine with autologous bone marrow transplant for the adjuvant treatment of high grade gliomas of the central nervous system. Cancer Treat. Rep., 1987. 71: p. 183-185.
19. Moolten, F., Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res., 1986. 46: p. 5276-5281.
20. Hasegawa, Y., et al., Gene transfer of herpes simplex virus type I thymidine kinase gene as a drug sensitivity gene into human lung cancer cell lines using retroviral vectors. Am. J. Respir. Cell Mol. Biol., 1983. 8: p. 655-661.
21. Smythe, W.R., et al., Use of Recombinant Adenovirus to Transfer the HSV-Thymidine Kinase Gene to Thoracic Neoplasms: An Effective In Vitro Drug Sensitization System. Cancer Res., 1994. 54: p. 2055-2059.
22. Smythe, W.R., et al., Treatment of Experimental Human Mesothelioma Using Adenovirus Transfer of the Herpes Simplex-Thymidine Kinase Gene. Cancer Res., 1994. in press.
23. Caruso, M., et al., Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA, 1993. 90: p. 7024-7028.
24. Abe, A., et al., Transduction of a drug-sensitive toxic gene into human leukemia cell lines with a novel retroviral vector. Proc. Soc. Exp. Biol. Med., 1993. 203(3): p. 354-359.
25. Golumbek, P.T., et al., Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. Journal of Immunotherapy, 1992. 12: p. 224-230.
26. Myklebust, A.T., A. Godal, and O. Fodstad, Targeted therapy with immunotoxins in a nude rat model for leptomeningeal growth of human small cell lung cancer. Cancer Research, 1994. 54: p. 2146-2150.
27. Barba, D., et al., Thymidine kinase-mediated killing of rat brain tumors. J. Neurosurg., 1993. 79: p. 729-735.
28. Barba, D., et al., Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Nat'l. Acad. Sci. USA, 1994. 91: p. 4348-4352.
29. Culver, K.W., et al., In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science, 1992. 256: p. 1550-1552.
30. Takamiya, Y., et al., An experimental model of retrovirus gene therapy for malignant brain tumors. J. Neurosurg., 1993. 79: p. 104-110.
31. Takamiya, Y., et al., Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. Journal of Neuroscience Research, 1992. 33: p. 493-503.
32. Chen, S.-H., et al., Gene Therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. 3054-57. Proc Nat Acad Sci. 1994. 91: p. 3054-57.
33. Freeman, S., et al., The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res., 1993. 53: p. 5274-5283.
34. Rubin, B.A. and L.B. Rorke, Adenovirus Vaccines, in Vaccines. S.A. Plotkin and E.A. Mortimer, Editor. 1994, W.B. Saunders: Philadelphia, p. 474-502.
35. Rorke, L.B., B.A. Rubin, and J. Myers, Neurovirulence of adenoviruses. J. Neuropathol. Exp. Neurol., 1973. 32: p. 161-162.
36. Akli, S., et al., Transfer of a foreign gene into the brain using adenovirus vectors. Nature Genetics, 1993. 3: p. 224-228.
37. Le Gal La Salle, G., et al., An adenovirus vector for gene transfer into neurons and glia in the brain. Science, 1993. 259: p. 988-990.
38. Bajocchi, G., S.H. Feldman, and R.G. Crystal, Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors. Nature Genetics, 1993. 3: p. 229-234.
39. Davidson, B.L., et al., A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nature Genetics, 1993. 3: p. 219-223.
40. 1H MRS and MRI. in press, 1994.
41. Zabner, J., et al., Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelial of patients with cystic fibrosis. Cell, 1993. 75: p. 207-216.
42. Simon, R.H., et al., Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: toxicity study. Human Gene Therapy, 1993. 4: p. 771-780.
43. Aronen, H.J., et al., Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology, 1994. 191: p. 41-51.
44. Alavi, J., et al., Positron emission tomography in patients with glioma. Cancer, 1988. 62: p. 1074-78.
45. Patronas, N.J., et al., [18F] Fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology, 1992. 144: p. 885-889.
46. Abe, Y., T. Matsuzawa, and T. Fujiwara, Clinical assessment of therapeutic effects in cancer using 18F-2-fluoro-2-deoxy-D-glucose and positron emmision tomography: preliminary study of lung cancer. Int. J. Rad. One. Biol. Phys., 1990. 19: p. 1005-1010.
47. Rozenthal, J.M., J.D. Cohen, and M.P. Mehta, Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme. J. Neuro. Onc., 1993. 15: p. 57-66.
48. Lexa, F.J., R.I. Grossman, and A.C. Rosenquist, MR of Wallerian degeneration in the feline visual system: characterization by magnetization transfer rate with histopathologic correlation. A.J.N.R., 1994. 15: p. 210-212.
49. Reivich, M., et al. The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ. Res., 1979. 44(1): p. 127-37.
50. Sokoloff, L., et al., The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem., 1977. 28(5): p. 897-916.
51. Huang, S.C., et al., Noninvasive determination of local cerebral metabolic rate of glucose in man. Am. J. Physiol., 1980. 238(1): p. E69-82.
52. Yang, Y., et al., Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene expression. Proc. Nat'l Acad. Sci. USA, 1994. 91(10): p. 4407-4411.
53. Engelhardt, J.F., L. Litzky, and W. J.M., Prolonged transgene expression in cotten rat lung with recombinant adenovirus defective in E2a. Human Gene Therapy, 1994. in press.
54. Horwitz, M.S., Adenoviruses, in Virology, B.N. Fields, et al., Editor. 1992, Raven Press: New York. p. 1723-1740.
55. Faulkner, R. and C.E. van Rooyen, Adenoviruses types 3 and 5 isolated from the cerebrospinal fluid of children. Canadian Med. Association Journal, 1962. 87: p. 1123-1125.
56. Kelsey, D.S., Adenovirus meningoencephalitis. Pediatrics, 1978. 61(2): p. 291-3.
57. Soeur, M., et al., Meningoencephalitis and meningitis due to adenovirus type 5 in two immunocompetent adults. Acta Neurol. Belg., 1991. 91: p. 141-150.
58. Davis, D., P.J. Henslee, and W.R. Markesberg, Fatal meningoencephalitis in a bone marrow transplant patient. Ann. Neurol, 1988. 23: p. 385-389.
59. Anders, K.H., et al., Adenovirus encephalitis and widespread ependymitis in a child with AIDS. Peadiatric Neurosurg., 1991.16: p. 316-320.
60. Roos, R., et al., Isolation of an adenovirus 32 strain from human brain in a case of subacute encephalitis. Proc. Soc. Exp. Biol. Med., 1972. 131: p. 636-640.